Unilever China

Established over 100 years ago, we are one of the world’s largest consumer goods companies. We are known for our great brands and our belief that doing business the right way drives superior performance.

Fresenius Kabi China

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients.

Intuitive Fosun

Intuitive Surgical is the pioneer and global leader in robotic-assisted minimally invasive surgery. The company designs, manufactures and sells da Vinci ® surgical robots. Shanghai Fosun Pharmaceutical is a leading healthcare group strategically comprising the complete value chain. Intuitive Surgical-Fosun will initially produce a less invasive and more flexible robotic catheter platform targeting early diagnosis and treatment of lung cancer.

SAIC-GM-Wuling Automobile Co., Ltd.

上汽通用五菱汽车股份有限公司于2002年11月18日正式成立，是由上海汽车集团股份有限公司、通用汽车（中国）投资有限公司、广西汽车集团共同组建的中中外合资企业。公司连续14年保持国内单一车企销量冠军，总销量突破2900万辆，是拥有最多用户的中国汽车企业。合资以来累计利税超过1300亿元。公司拥有柳州河西总部、柳州宝骏基地、青岛分公司和重庆分公司四大制造基地，同时积极响应“一带一路”号召，于2017年在印尼成立SGMW印尼汽车有限公司。公司愿景为“成为全球创新、跨界、体验的标杆公司”。拥有五菱和新宝骏两大品牌：五菱品牌以“人民需要什么，五菱就造什么”为品牌精神，持续深耕人民需求；新宝骏品牌以“智能网联、智能驾控、跨界融合”为标签，致力于成为“智慧汽车先导者”。公司秉承“责任至上，全员公益”，不断践行企业社会责任，坚守企业责任之道，在企业快速发展的同时，反哺社会、回馈大众。在全国抗击新型冠状肺炎之初，公司凭借卓越表现，获得国家《全国抗击新冠肺炎疫情先进集体》称号。

School of Management, Fudan University

School of Management, Fudan University has forged a pioneering path to lead and propel the development of business education in China and the world. In 2020, the School took the lead in launching the “Sci-Tech Innovation Strategy”. In 2024, the wall-less Zhengli Campus—connecting academia, industry, and community—marked a new milestone. Guided by “Enlightening for Truth, Pioneering for Change”, the School continues its journey toward excellence.

Novartis (China)

诺华是一家全球领先的创新药物公司。我们的使命是创想医药未来，改善人们生活质量，延长人类寿命。2023年，全球有约2.84亿患者受益于诺华的产品。
秉持“承诺中华”的理念，诺华从研发、生产到业务发展，全面布局中国市场。
我们致力于为中国患者提供高临床价值的创新药。自1987年以来，诺华已有超过100款创新药物及新适应症在华获批。
通过深化与中国医疗生态系统各方的多方位合作，诺华不断助力提升疾病诊疗标准，积极履行企业责任，推动健康中国战略的实施，从而为中国发展做出切实而积极的贡献。